Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2009

View Archived Issues

Novel anti-EGFR antibody GA-201 active in tumor models

P53-armed oncolytic adenovirus CGCT-04 induces apoptosis in cancer cells

Studies explore pharmacokinetics, antitumor activity of novel formulation of SN-38

Roche reviews Q1 activity

Speedel describes novel renin inhibitors as antihypertensive agents

Ark Therapeutics enrolls first patient into phase III study of Trinam in end-stage renal disease

SemBioSys' reports results from preclinical studies of plant-derived Apo AI(Milano)

Prospect Therapeutics to action off assets in June 2009

Rexahn enrolls 50% of patients in phase IIa trial of Serdaxin in MDD

Albert Einstein School of Medicine to conduct study of nanoviricide in HSV keratitis

Koronis SAB confirms positive results from studies of HIV drug KP-1461

Celator and Cephalon enter agreement in drug development and life-cycle management

Merck & Co. discovers novel quinolizidinone compounds for the treatment of Alzheimer's disease

Novartis presents novel ALK5 inhibitors for the treatment of liver fibrosis

Ferrer claims melatonin receptor agonists for the treatment of sleep disorders

Schering-Plough describes novel kinesin spindle protein inhibitors for cancer treatment

Oritavancin efficacy detailed in ECCMID presentations

Novel monobactam antibiotic BAL-0030072 shows potent activity against multiresistant bacteria

Aerie Pharmaceuticals reports on discovery and preclinical activity of glaucoma agent AR-12286

Fusion protein KH-902 well tolerated in patients with choroidal neovascularization

Vical advances H1N1 pandemic influenza (swine flu) vaccine program

FDA accepts for review SkyePharma's NDA for Flutiform in persistent asthma

Johnson & Johnson to acquire Cougar Biotechnology

Health Canada approves PolyMedix's CTA for phase Ib clinical study of PMX-30063

Genzyme submits information requested by FDA for Lumizyme

Human Genome Sciences submits BLA to FDA for ABthrax inhalation anthrax treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...